Published in Proc Natl Acad Sci U S A on March 15, 1992
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A (1992) 3.19
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol (1994) 2.52
Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol (1995) 1.99
Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol (1994) 1.82
Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res (2008) 1.73
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol (2002) 1.69
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol (1995) 1.52
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol (1996) 1.46
Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol (1996) 1.45
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol (2004) 1.31
Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases. J Virol (2000) 1.16
CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120. Proc Natl Acad Sci U S A (1998) 1.15
Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci U S A (1999) 1.14
Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity. J Virol (1998) 1.09
Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection. Retrovirology (2008) 1.08
High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology (2007) 1.05
Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci U S A (2007) 0.99
Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol (2005) 0.99
HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. J Virol (2010) 0.92
Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome. J Virol (1996) 0.89
The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem (2011) 0.87
Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology (2009) 0.86
Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol (1993) 0.86
Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One (2014) 0.83
Experimental Estimation of the Effects of All Amino-Acid Mutations to HIV's Envelope Protein on Viral Replication in Cell Culture. PLoS Pathog (2016) 0.82
Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques. Virology (2014) 0.81
Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120. Int J Biol Sci (2010) 0.78
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops. PLoS One (2015) 0.76
A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol (1975) 90.35
Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A (1985) 5.10
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72
Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature (1987) 2.61
Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem (1988) 2.48
Envelope sequences of two new United States HIV-1 isolates. Virology (1988) 2.44
Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci U S A (1987) 2.25
Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1988) 1.86
Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J (1988) 1.81
Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science (1984) 1.77
Correlation of glycosylation forms with position in amino acid sequence. J Cell Biol (1983) 1.44
Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs. J Infect Dis (1988) 1.15
Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins. J Gen Virol (1991) 1.04
Processing and secretion of envelope glycoproteins of human immunodeficiency virus type 1 in the presence of trimming glucosidase inhibitor deoxynojirimycin. Intervirology (1989) 1.01
Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response. J Virol (1986) 0.99
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Does housestaff discontinuity of care increase the risk for preventable adverse events? Ann Intern Med (1994) 10.29
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
HUMAN TOXOPLASMOSIS: OCCURRENCE IN INFANTS AS AN ENCEPHALOMYELITIS VERIFICATION BY TRANSMISSION TO ANIMALS. Science (1939) 7.95
Toxoplasmic encephalomyelitis: III. A new case of granulomatous encephalomyelitis due to a protozoon. Am J Pathol (1939) 7.25
Cyclin activation of p34cdc2. Cell (1990) 6.87
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 6.38
Contaminant blood cultures and resource utilization. The true consequences of false-positive results. JAMA (1991) 6.28
A family of cAMP-binding proteins that directly activate Rap1. Science (1998) 6.12
Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell (2000) 5.92
RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell (1995) 5.73
Complete genome sequence of Caulobacter crescentus. Proc Natl Acad Sci U S A (2001) 5.58
Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Male circumcision: an acceptable strategy for HIV prevention in Botswana. Sex Transm Infect (2003) 5.26
Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J (1997) 5.25
PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 5.18
Spatio-temporal images of growth-factor-induced activation of Ras and Rap1. Nature (2001) 4.83
Physician reporting compared with medical-record review to identify adverse medical events. Ann Intern Med (1993) 4.60
Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med (2000) 4.43
Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31. EMBO J (1999) 4.34
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
THE RAPID PRODUCTION OF ACUTE DISSEMINATED ENCEPHALOMYELITIS IN RHESUS MONKEYS BY INJECTION OF HETEROLOGOUS AND HOMOLOGOUS BRAIN TISSUE WITH ADJUVANTS. J Exp Med (1947) 4.16
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med (2000) 4.14
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Structure of serum response factor core bound to DNA. Nature (1995) 3.94
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer (1999) 3.47
Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest (1994) 3.31
Histochemical Studies on Tissue Enzymes: III. A Study of the Distribution of Acid Phosphatases with Special Reference to the Nervous System. Am J Pathol (1943) 3.31
Predicting bacteremia in hospitalized patients. A prospectively validated model. Ann Intern Med (1990) 3.31
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
Recruitment of HAT complexes by direct activator interactions with the ATM-related Tra1 subunit. Science (2001) 3.17
Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem (1991) 3.06
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med (1995) 3.03
Rapid classification of positive blood cultures. Prospective validation of a multivariate algorithm. JAMA (1992) 3.02
Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med (1993) 3.00
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Specificity of DNase I. Estimation of nucleosides present at the 5'-phosphate terminus of a limit digest of DNA by DNase I. J Biochem (1966) 2.96
Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93
Feline oncornavirus-associated cell membrane antigen: evidence for an immunologically crossreactive feline sarcoma virus-coded protein. Proc Natl Acad Sci U S A (1977) 2.93
Rapid Production of Acute Disseminated Encephalomyelitis in Rhesus Monkeys by Injection of Brain Tissue With Adjuvants. Science (1946) 2.88
Phospholipase C assay using p-nitrophenylphosphoryl-choline together with sorbitol and its application to studying the metal and detergent requirement of the enzyme. Anal Biochem (1976) 2.87
Heterogeneity of therapeutic responses in asthma. Br Med Bull (2000) 2.86
Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev (1998) 2.82
Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology (2006) 2.82
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia (2003) 2.80
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67
Malaria infection of the mosquito Anopheles gambiae activates immune-responsive genes during critical transition stages of the parasite life cycle. EMBO J (1998) 2.62
Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol (1990) 2.60
The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol (1992) 2.51
Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room. Am J Cardiol (1987) 2.50
Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science (1983) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet (1986) 2.48
A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci U S A (1998) 2.47
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax (1997) 2.46
A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med (1988) 2.46
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol Cell Biol (1996) 2.44
Patient and house officer attitudes on physician attire and etiquette. JAMA (1987) 2.44
The ubiquitin-related protein RUB1 and auxin response in Arabidopsis. Science (1998) 2.42
The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res (1979) 2.41
Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol (2003) 2.40
Prediction of the need for intensive care in patients who come to the emergency departments with acute chest pain. N Engl J Med (1996) 2.39
A seronegative case of HIV-1 subtype C infection in Botswana. Clin Infect Dis (2007) 2.39
Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg (1999) 2.38
Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial. J Neurosurg (1993) 2.37
Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm Res (1998) 2.36
Horizontal transmission of feline leukaemia virus. Nature (1973) 2.34